|
12 Companies |
|
26 Products |
|
26 Products |
|
43 Mechanisms of Action |
|
1 Trial |
|
153 News |
|
| 1234» |
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 29, 2023
P2/3, N=250, Active, not recruiting, Sponsor: RenJi Hospital
Trial completion date: Oct 2022 --> Jan 2029
- Biomarker, Trial completion, Enrollment change, BRCA Biomarker: Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (clinicaltrials.gov) - Sep 9, 2019
P=N/A, N=17, Completed, Sponsor: University of Washington
Trial completion date: Oct 2022 --> Jan 2029 Active, not recruiting --> Completed | N=30 --> 17
- Biomarker, Enrollment open, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Sep 9, 2019
P2b, N=200, Recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | N=30 --> 17 Not yet recruiting --> Recruiting
- | Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Phase classification, Enrollment change, Trial withdrawal, Biopsy: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection (clinicaltrials.gov) - Mar 26, 2019
P1, N=0, Withdrawn, Sponsor: Columbia University
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 14, 2019
P2/3, N=250, Active, not recruiting, Sponsor: RenJi Hospital
Phase classification: P=N/A --> P1 | N=20 --> 0 | Recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Enrollment change, Surgery: Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer (clinicaltrials.gov) - Jan 31, 2019
P2, N=0, Withdrawn, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting N=25 --> 0
- | Biomarker, Trial completion: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=316, Completed, Sponsor: Mayo Clinic
N=25 --> 0 Active, not recruiting --> Completed
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 15, 2018
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Active, not recruiting --> Completed Trial primary completion date: Jul 2018 --> Oct 2018
- | Trial completion: Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors (clinicaltrials.gov) - Aug 9, 2018
P2, N=52, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Jul 2018 --> Oct 2018 Active, not recruiting --> Completed
- | Trial termination: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Jul 17, 2018
P2, N=1, Terminated, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Completed --> Terminated; Early termination leading to small number of subjects analyzed
- | letrozole / Generic mfg.
Trial completion: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Mar 27, 2018
P2, N=108, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Completed --> Terminated; Early termination leading to small number of subjects analyzed Active, not recruiting --> Completed
- | Biomarker, Trial primary completion date: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Feb 6, 2018
P=N/A, N=300, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: Sep 2017 --> Sep 2018
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Dec 21, 2017
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Jul 2017 --> Jul 2018
- | letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Dec 12, 2017
P3, N=8028, Completed, Sponsor: International Breast Cancer Study Group
Trial primary completion date: Jul 2017 --> Jul 2018 Active, not recruiting --> Completed
- | Biomarker, Trial completion, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Nov 24, 2017
P2b, N=208, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ritonavir / Generic mfg.
Biomarker, Trial completion, Enrollment change, Surgery: Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=28, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=52 --> 28
- | Trial completion, Enrollment change, Surgery: Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer (clinicaltrials.gov) - Aug 21, 2017
P2, N=263, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting --> Completed | N=52 --> 28 Recruiting --> Completed | N=352 --> 263
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Trial primary completion date: Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast (clinicaltrials.gov) - Aug 7, 2017
P1, N=17, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed | N=352 --> 263 Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> Nov 2011
- | Soltamox (tamoxifen citrate) / Jazz
Trial primary completion date: Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen (clinicaltrials.gov) - Aug 1, 2017
P2, N=501, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Jul 2011 --> Nov 2011 Trial primary completion date: Mar 2010 --> Sep 2010
- | letrozole / Generic mfg.
Trial primary completion date: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Jul 13, 2017
P2, N=108, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Mar 2010 --> Sep 2010 Trial primary completion date: Jun 2017 --> Aug 2016
- ||||||| Trial completion, Trial primary completion date: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (clinicaltrials.gov) - Jul 13, 2017
P3, N=961, Completed, Sponsor: German Breast Group
Trial primary completion date: Jun 2017 --> Aug 2016 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016
- | Soltamox (tamoxifen citrate) / Jazz
Trial completion, Phase classification: Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen (clinicaltrials.gov) - Jul 2, 2017
P2, N=501, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P2
- | letrozole / Generic mfg.
Trial completion: WISE: Letrozole in Preventing Breast Cancer in Postmenopausal Women (clinicaltrials.gov) - Jun 28, 2017
P2, N=49, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Phase classification: PN/A --> P2 Recruiting --> Completed
- | Trial completion: Pain After Tumescent Mastectomy or Standard Mastectomy in Women With Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=74, Completed, Sponsor: University of California, Davis
Recruiting --> Completed Recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Jun 20, 2017
P2, N=1, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 1 | Trial primary completion date: Jan 2018 --> Jun 2017
- | Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Jun 2, 2017
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed | N=10 --> 1 | Trial primary completion date: Jan 2018 --> Jun 2017 Trial primary completion date: Apr 2017 --> Jul 2017
- | Biomarker, Trial completion, Trial primary completion date: Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ (clinicaltrials.gov) - May 17, 2017
P=N/A, N=500, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Trial primary completion date: Apr 2017 --> Jul 2017 Not yet recruiting --> Completed | Trial primary completion date: Apr 2011 --> Apr 2010
- | Trial completion, Enrollment change, Trial primary completion date: BCCR: Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer (clinicaltrials.gov) - May 15, 2017
P=N/A, N=4945, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Completed | Trial primary completion date: Apr 2011 --> Apr 2010 Recruiting --> Completed | N=999999 --> 4945 | Trial primary completion date: Dec 2020 --> Dec 2016
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 27, 2017
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Recruiting --> Completed | N=999999 --> 4945 | Trial primary completion date: Dec 2020 --> Dec 2016 N=160 --> 250 | Trial primary completion date: Dec 2016 --> Jul 2017
- | Enrollment change, IO biomarker, Surgery: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer (clinicaltrials.gov) - Mar 15, 2017
P=N/A, N=30, Completed, Sponsor: Wake Forest University Health Sciences
N=160 --> 250 | Trial primary completion date: Dec 2016 --> Jul 2017 N=70 --> 30
- | Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
N=70 --> 30 Trial primary completion date: Jan 2017 --> Apr 2017
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=132, Completed, Sponsor: RenJi Hospital
Trial primary completion date: Jan 2017 --> Apr 2017 Active, not recruiting --> Completed
- arzoxifene (LY353381) / Eli Lilly
Trial completion: Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Jan 13, 2017
P1, N=0, Completed, Sponsor: University of Kansas Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Trial primary completion date: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=300, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- Biomarker, Trial primary completion date, BRCA Biomarker: S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer (clinicaltrials.gov) - Nov 15, 2016
P2b, N=200, Active, not recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Sep 2015 --> Jan 2017
- Trial primary completion date: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Oct 19, 2016
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Jan 2017 Trial primary completion date: Jan 2017 --> Jan 2018
- Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
Enrollment open, Trial primary completion date, Biopsy: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection (clinicaltrials.gov) - Jul 29, 2016
P=N/A, N=20, Recruiting, Sponsor: Columbia University
Trial primary completion date: Jan 2017 --> Jan 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- | tamoxifen / Generic mfg.
Trial completion: Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease (clinicaltrials.gov) - Jul 11, 2016
P2, N=112, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed
- letrozole / Generic mfg.
Enrollment closed: DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) - Jun 22, 2016
P2, N=115, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Biomarker, Trial termination: Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Jun 11, 2016
P=N/A, N=20, Terminated, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Completed --> Terminated; low accrual
- ||||||| anastrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion: Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy (clinicaltrials.gov) - Jun 11, 2016
P3, N=3104, Completed, Sponsor: NSABP Foundation Inc
Completed --> Terminated; low accrual Active, not recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Combination therapy, Metastases: Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer (clinicaltrials.gov) - May 10, 2016
P2, N=132, Active, not recruiting, Sponsor: RenJi Hospital
Active, not recruiting --> Completed N=200 --> 132
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 7, 2016
P2, N=200, Active, not recruiting, Sponsor: RenJi Hospital
N=200 --> 132 Recruiting --> Active, not recruiting
- Biomarker, Trial primary completion date: Studying Biomarkers in Nipple Fluid, Urine, and Blood Samples From Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer and in Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=300, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2015 --> Sep 2016
- Biomarker, Trial completion, Enrollment change, Trial primary completion date: Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=20, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed | N=50 --> 20 | Trial primary completion date: Dec 2011 --> Jun 2011
- tamoxifen / Generic mfg.
Trial primary completion date, Gene Expression Profile, Surgery: Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=64, Active, not recruiting, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed | N=50 --> 20 | Trial primary completion date: Dec 2011 --> Jun 2011 Trial primary completion date: Nov 2014 --> May 2015
- Venofer (iron sucrose complex) / Daiichi Sankyo, CSL Behring
New trial, Biopsy: Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=20, Not yet recruiting, Sponsor: Columbia University
- Trial primary completion date: Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) - Oct 22, 2015
P2, N=10, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2014 --> May 2015 Trial primary completion date: Jan 2016 --> Jan 2017
- Trial termination, Surgery: Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ (clinicaltrials.gov) - Oct 22, 2015
P2, N=711, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; This study was terminated when the accrual goal for the low/intermediate grade stratum was reached. The high grade stratum was closed due to slow accrual.
- Enrollment change: SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=180, Completed, Sponsor: Southwest Oncology Group
The high grade stratum was closed due to slow accrual. N=420 --> 180